The Filing Desk

Lexaria Bioscience vs Rafael Holdings

Lexaria Bioscience LEXX · Rafael Holdings RFL · Pharmaceuticals

Rafael Holdings reported revenue of $1 million in fiscal 2026, 1.3 times Lexaria Bioscience's $1 million in fiscal 2025. Lexaria Bioscience's revenue grew 52.0% in its latest year, and Rafael Holdings' fell 4.7%. Lexaria Bioscience had an operating margin of -1683.0%, against -3822.5% at Rafael Holdings. Free cash flow was −$10 million at Lexaria Bioscience and −$30 million at Rafael Holdings. Their fiscal years end in different months (August 31 and July 31), so the periods don't line up exactly.

Side by side

Lexaria BioscienceRafael Holdings
Latest fiscal yearFY2025, Aug 31, 2025FY2026, Jul 31, 2026
Revenue$1M$1M
Revenue growth52.0%−4.7%
Revenue growth a year, last 5 years18.5%2.4%
Gross margin99.6%—
Operating margin−1,683.0%−3,822.5%
Net margin−1,686.0%−3,390.7%
Free cash flow−$10M−$30M
Free cash flow margin−1,483.9%−3,431.3%
Return on capital−929.6%—
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count45.3%74.7%
Last close$4.49$0.90
P/E at the last close——
Insider trades, last 12 months——
Piotroski F-score3 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Lexaria BioscienceRafael Holdings
Operating margin
Percent of revenue
Lexaria BioscienceRafael Holdings
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Lexaria BioscienceRafael Holdings

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Lexaria Bioscience and Rafael Holdings pages.